# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA3879985 | B | Inhibition of human KV1.5 expressed in HEK cells by patch clamp method | Homo sapiens | 5 | cell-based format | Patent Bioactivity Data | ||
2. | ALA3879990 | B | Inhibition of human KV4.2 expressed in HEK cells by patch clamp method | Homo sapiens | 5 | cell-based format | Patent Bioactivity Data | ||
3. | ALA3879991 | B | Inhibition of human H1 Na+ channel expressed in HEK cells by patch clamp method | Homo sapiens | 5 | cell-based format | Patent Bioactivity Data | ||
4. | ALA3879992 | T | Neurotoxicity in iv dosed Sprague-Dawley rat assessed as minimum infusion rate of the compound require for partial and complete convulsion | Rattus norvegicus | 45 | organism-based format | Patent Bioactivity Data | ||
5. | ALA3879993 | T | Neurotoxicity in iv dosed Sprague-Dawley rat assessed as total amount of drug infused at the point that partial or complete convulsions are first observed | Rattus norvegicus | 45 | organism-based format | Patent Bioactivity Data | ||
6. | ALA3879994 | F | Antiarrhythmic activity in iv dosed Sprague-Dawley rat coronary artery occlusion model administered via infusion for 5 mins starting 15 post surgery followed by coronary artery occlusion measured for 15 mins by electrocardiogram | Rattus norvegicus | 45 | organism-based format | Patent Bioactivity Data | ||
7. | ALA3879995 | A | Therapeutic index, ratio of neurotoxicity in iv dosed Sprague-Dawley rat assessed as total amount of drug infused at the point that partial or complete convulsions are first observed to 20 times ED50 for antiarrhythmic activity in iv dosed Sprague-Dawley rat coronary artery occlusion model | Rattus norvegicus | 45 | organism-based format | Patent Bioactivity Data |